Update: 27.12.2021
Last week: 50th week 2021 (13.12.2021 - 19.12.2021)
Last full month: Nov 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | ||||||||
| WoW | 1 839 | 4.0% | 45.1% | -0.8 | 785 583 | -0.8% | 74.9% | -1.5 |
| MoM | 7 959 | -19.1% | 47.1% | -5.7 | 3 472 255 | -18.8% | 76.7% | -3.8 |
| YTD | 114 310 | -24.0% | 56.0% | -5.8 | 44 175 606 | -0.0% | 80.4% | -0.2 |
| MAT | 120 541 | -23.5% | 56.2% | -5.5 | 46 239 885 | 0.2% | 80.5% | -0.1 |
| CAPSICAM | ||||||||
| WoW | 25 572 | 4.9% | 4.1% | 0.1 | 10 377 442 | 5.2% | 4.4% | 0.1 |
| MoM | 95 769 | -2.9% | 3.5% | 0.3 | 38 687 899 | -3.0% | 3.7% | 0.3 |
| YTD | 1 018 935 | -19.3% | 3.1% | -0.3 | 420 088 404 | -5.3% | 3.5% | -0.2 |
| MAT | 1 085 042 | -18.3% | 3.2% | -0.3 | 447 729 933 | -3.6% | 3.5% | -0.1 |
| MILDRONATE | ||||||||
| WoW | 107 950 | 9.7% | 13.2% | 1 | 41 950 828 | 9.7% | 18.5% | 1.2 |
| MoM | 452 608 | -4.7% | 12.5% | -0.2 | 173 520 666 | -5.0% | 17.3% | 0.2 |
| YTD | 4 632 174 | 14.7% | 9.3% | 1.5 | 1 869 731 455 | 20.7% | 14.1% | 2.4 |
| MAT | 4 875 723 | 16.1% | 9.2% | 1.4 | 1 972 388 219 | 22.7% | 14.1% | 2.3 |
| SULFARGIN | ||||||||
| WoW | 4 420 | 22.2% | 1.3% | 0.3 | 2 132 704 | 21.0% | 1.9% | 0.4 |
| MoM | 12 818 | -5.2% | 0.9% | 0 | 6 444 451 | -5.0% | 1.3% | 0 |
| YTD | 156 123 | -22.2% | 0.8% | -0.2 | 75 903 003 | -8.8% | 1.2% | -0.1 |
| MAT | 164 717 | -20.6% | 0.8% | -0.2 | 79 884 419 | -6.8% | 1.2% | -0.1 |
| VIPROSAL | ||||||||
| WoW | 32 491 | 0.3% | 5.2% | -0.1 | 12 936 155 | 2.0% | 5.5% | 0 |
| MoM | 141 907 | -0.9% | 5.2% | 0.5 | 54 642 364 | 1.6% | 5.3% | 0.6 |
| YTD | 1 184 553 | -12.9% | 3.6% | 0 | 447 608 725 | -2.9% | 3.7% | -0.1 |
| MAT | 1 249 507 | -12.2% | 3.6% | 0 | 472 799 200 | -1.3% | 3.7% | -0.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 1 839 | 4.0% | 45.1% | -0.8 | 785 583 | -0.8% | 74.9% | -1.5 |
| CAPSICAM | 25 572 | 4.9% | 4.1% | 0.1 | 10 377 442 | 5.2% | 4.4% | 0.1 |
| MILDRONATE | 107 950 | 9.7% | 13.2% | 1 | 41 950 828 | 9.7% | 18.5% | 1.2 |
| SULFARGIN | 4 420 | 22.2% | 1.3% | 0.3 | 2 132 704 | 21.0% | 1.9% | 0.4 |
| VIPROSAL | 32 491 | 0.3% | 5.2% | -0.1 | 12 936 155 | 2.0% | 5.5% | 0 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 7 959 | -19.1% | 47.1% | -5.7 | 3 472 255 | -18.8% | 76.7% | -3.8 |
| CAPSICAM | 95 769 | -2.9% | 3.5% | 0.3 | 38 687 899 | -3.0% | 3.7% | 0.3 |
| MILDRONATE | 452 608 | -4.7% | 12.5% | -0.2 | 173 520 666 | -5.0% | 17.3% | 0.2 |
| SULFARGIN | 12 818 | -5.2% | 0.9% | 0 | 6 444 451 | -5.0% | 1.3% | 0 |
| VIPROSAL | 141 907 | -0.9% | 5.2% | 0.5 | 54 642 364 | 1.6% | 5.3% | 0.6 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 114 310 | -24.0% | 56.0% | -5.8 | 44 175 606 | -0.0% | 80.4% | -0.2 |
| CAPSICAM | 1 018 935 | -19.3% | 3.1% | -0.3 | 420 088 404 | -5.3% | 3.5% | -0.2 |
| MILDRONATE | 4 632 174 | 14.7% | 9.3% | 1.5 | 1 869 731 455 | 20.7% | 14.1% | 2.4 |
| SULFARGIN | 156 123 | -22.2% | 0.8% | -0.2 | 75 903 003 | -8.8% | 1.2% | -0.1 |
| VIPROSAL | 1 184 553 | -12.9% | 3.6% | 0 | 447 608 725 | -2.9% | 3.7% | -0.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 120 541 | -23.5% | 56.2% | -5.5 | 46 239 885 | 0.2% | 80.5% | -0.1 |
| CAPSICAM | 1 085 042 | -18.3% | 3.2% | -0.3 | 447 729 933 | -3.6% | 3.5% | -0.1 |
| MILDRONATE | 4 875 723 | 16.1% | 9.2% | 1.4 | 1 972 388 219 | 22.7% | 14.1% | 2.3 |
| SULFARGIN | 164 717 | -20.6% | 0.8% | -0.2 | 79 884 419 | -6.8% | 1.2% | -0.1 |
| VIPROSAL | 1 249 507 | -12.2% | 3.6% | 0 | 472 799 200 | -1.3% | 3.7% | -0.1 |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs